TargetMol

Ridogrel

Product Code:
 
TAR-T34327
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T34327-100mg100mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T34327-50mg50mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Lidogrell is a dual-acting agent that can be used to prevent systemic thromboembolism and as an adjunct to thrombolytic therapy in acute myocardial infarction.
CAS:
110140-89-1
Formula:
C18H17F3N2O3
Molecular Weight:
366.34
Purity:
0.98
SMILES:
OC(=O)CCCCON=C(c1cccnc1)c1cccc(c1)C(F)(F)F

References

van der Wieken LR, Simoons ML, Laarman GJ, Van den Brand M, Nijssen KM, Dellborg M, Hermens W, Vrolik W. Ridogrel as an adjunct to thrombolysis in acute myocardial infarction. Int J Cardiol. 1995 Nov 24;52(2):125-34. PubMed PMID: 8749872. Tytgat GN, Van Nueten L, Van De Velde I, Joslyn A, Hanauer SB. Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies. Aliment Pharmacol Ther. 2002 Jan;16(1):87-99. PubMed PMID: 11856082. Naran NH, Chetty N. The in vitro effect of ridogrel on platelet function in normocholesterolaemic and familial hypercholesterolaemic type IIa subjects. Thromb Res. 1997 Dec 1;88(5):399-407. PubMed PMID: 9556227. Carty E, Rampton DS, Schneider H, Rutgeerts P, Wright JP. Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease. Aliment Pharmacol Ther. 2001 Sep;15(9):1323-9. PubMed PMID: 11552902.